The case for & against
Bull & Bear analysis
Synexis Inc. (NASDAQ: SYN) is a biopharmaceutical company specializing in the development and commercialization of innovative antifungal therapies, notably its flagship product, Brexafem (ibrexafunger). The company is targeting significant unmet medical needs within women's health, particularly related to recurrent vulvovaginal candidiasis (rVVC) and invasive candidiasis, during a time when the rising incidence of antimicrobial resistance is a growing global health concern. With a focus on expanding its clinical strategy, Synexis is well-positioned in the antifungal market, aiming to benefit from both recent technological advancements and growing market demand.
Bull says
- ↑Q3 prescriptions rose 30% QoQ to 5,100, reflecting strong uptake.
- ↑Net product revenue grew 23% QoQ to $1.6M in Q3.
- ↑Cash balance of $96M funds operations into Q2 2024.
- ↑FDA PDUFA on Nov 30, 2022 may expand Brexafem to rVVC prevention.
- ↑Undervaluation indicated by 1.45 book-to-price and positive profitability metrics.
- ↑Prescriber base expanded 11% QoQ to 2,500 clinicians.
Bear says
- ↓Earnings yield is negative and growth factor is below zero.
- ↓High short interest (1.70) signals market skepticism.
- ↓Q4 sales may slow after halting Amplitude promotional support.
- ↓R&D spending reached $6.4M in Q3, pressuring cash burn.
- ↓Competition from Mycovia, Pfizer, and Gilead threatens market share.
- ↓Small market cap heightens liquidity risk per size factor.
Earnings Call · Q3 2021 · Mgmt. Guidance
Transcript signals
Bull points
- This is our first quarter ever to report product sales. We are very proud of the progress and excited about it.
- the launch is proceeding well. This was a partial quarter for us, and we ended the quarter strong, and already see indications of a strong positive trajectory of sales in the fourth quarter.
- For the third quarter of 2021, its first quarter post-launch, BrexFM generated $516,000 in net sales.
Bear points
- Our synergist study Evaluating oral ibrexafungur in combination with voriconazole for the treatment of invasive pulmonary aspergillosis has not enrolled as rapidly as initially projected.
- The prioritization of hospital resources towards addressing COVID-19 pandemic has impacted the ability of many institutions to focus on screening and enrollment of patients into clinical trials, including Synergia.
- I would expect that at this point we don't expect that it's going to be the majority of the patients enrolled because physicians, as you can understand, this is a new condition or a new combination of conditions, which is COVID and invasive pulmonary aspergillosis.